Novo Nordisk:“Algeria unconcerned by decision to withdraw Insulin production from 13 countries”

The importance of the buoyant Algerian market has pushed the Novo Nordisk Region International Operation to choose Algeria among several other countries as a privileged place to develop the manufacture of insulin, officials of the company said.

According to the Senior Vice president of Novo Nordisk Region International Operation, JesperHoiland, their decision to choose Algeria will be “a unique experience of its kind in North Africa and Middle East, and is an example;” before encouraging other countries with intentions to invest in pharmaceutical laboratories to consider Algeria as a reference.

Such countries as Denmark, USA, France, China, Brazil and Japan which are partners for the production of insulin were however overrun by Algeria to produce insulin for the company. It is important to note that Denmark’s Novo Nordisk has established laboratories in Algeria since 1996.

The Company’s senior vice president also hailed the bilateral relationship existing between Algeria and Denmark describing it as “historic”.

Mr Jesper Hoiland insisted on the necessity to enlarge the scope of the relations between the two countries through other initiatives in Algeria after the Algerian authorities’planned inspection visit to the laboratories of the parent company in the next few days including the plant located 100 km from the Danish capital which produces by itself, more than half of the world’soutput of insulin.

He added that the ongoing fruitful partnership with Algeria’s pharmaceutical group Saidal was based on a long-term cooperation in order to ensure that the same technological process would be used for the manufacture of all types of medicines for the benefit of all the Algerian patients.

Novo Nordisk is also closely collaborating with the Algerian Ministry of Health and the pharmaceutical company’s last activity was a clinical trial developed for Muslim diabetics during the holy month of fasting of Ramadan to achieve proper management of blood glucoses.